The C-X-3-C Motif Chemokine Receptor pipeline drugs market research report outlays comprehensive information on the C-X-3-C Motif Chemokine Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the C-X-3-C Motif Chemokine Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Oncology, and Immunology which include the indications Myocardial Infarction, Atherosclerosis, Alzheimer’s Disease, Secondary Progressive Multiple Sclerosis (SPMS), Ovarian Cancer, Chronic Lymphocytic Leukemia (CLL), and Inflammation. It also reviews key players involved in C-X-3-C Motif Chemokine Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The C-X-3-C Motif Chemokine Receptor pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 3, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
C-X-3-C Motif Chemokine Receptor overview
CX3CR1, also known as fractalkine receptor or GPR13, is a transmembrane protein belonging to the G protein-coupled receptor (GPCR) family. It is the sole member of the CX3C chemokine receptor subfamily and plays a crucial role in various physiological processes, including immune cell trafficking, neuronal communication, and neuroinflammation.
For a complete picture of C-X-3-C Motif Chemokine Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
